Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Third Rock Ventures Rolls Its Own

This article was originally published in Start Up

Executive Summary

Third Rock Ventures has raised $1.3 billion by going all-in on early-stage biotech with a homegrown company strategy that requires that its own people run many of its portfolio companies after launch. It’s hard to say definitively that the strategy is working, but then again, its investors just re-upped for a new half-billion-dollar fund.

You may also be interested in...



Third Rock’s Mark Levin Warns of System-Wide Failure To Support Young Biomedical Companies

Third Rock Partner Mark Levin is excited about emerging science, but somewhat pessimistic about the environment for companies pursuing it.

“Brown Fat” Attracts Start-Up Interest, Highlighted At ADA 2012

Bruce Spiegelman, co-founder of the start-up Ember Therapeutics and winner of ADA’s prestigious Banting Award, described how his lab at Harvard discovered the hormone irisin, which appears to be a key regulator of fat metabolism and may be responsible for beneficial functions of “brown” fat.

Genentech, Constellation Enter Largest Epigenetics Tie-Up Yet

For $95 million guaranteed, Genentech gains rights to broad research in the emerging field over a three-year period, as well as an option to acquire the start-up outright.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC092476

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel